2025-04-11 15:55:05,356 - NCTProcessor - INFO - Processing data/Hemonc_new_with_authors.csv with gemini-2.0-flash
2025-04-11 15:55:05,356 - NCTProcessor - INFO - Reading CSV file: data/Hemonc_new_with_authors.csv
2025-04-11 15:55:05,359 - NCTProcessor - INFO - Preparing input data...
2025-04-11 15:55:05,375 - NCTProcessor - INFO - Processing 5 examples using gemini-2.0-flash with tools using 8 threads...
2025-04-11 15:55:05,375 - google_genai.models - INFO - AFC is enabled with max remote calls: 10.
2025-04-11 15:55:05,376 - google_genai.models - INFO - AFC is enabled with max remote calls: 10.
2025-04-11 15:55:05,376 - google_genai.models - INFO - AFC is enabled with max remote calls: 10.
2025-04-11 15:55:05,377 - google_genai.models - INFO - AFC is enabled with max remote calls: 10.
2025-04-11 15:55:05,377 - google_genai.models - INFO - AFC is enabled with max remote calls: 10.
2025-04-11 15:55:07,772 - google_genai.models - INFO - AFC remote call 1 is done.
2025-04-11 15:55:07,773 - google_genai.models - INFO - AFC remote call 1 is done.
2025-04-11 15:55:07,852 - google_genai.models - INFO - AFC remote call 1 is done.
2025-04-11 15:55:07,933 - google_genai.models - INFO - AFC remote call 1 is done.
2025-04-11 15:55:08,598 - google_genai.models - INFO - AFC remote call 1 is done.
2025-04-11 15:55:08,599 - NCTProcessor - INFO - Processing results...
2025-04-11 15:55:08,600 - NCTProcessor - INFO - Extracting info from response (task: track_second_authors_multiple_pmids_any):
Based on the search results, the most relevant paper appears to be the phase III trial mentioned in multiple snippets, which compares Cisplatin/Topotecan with and without Hydralazine/Valproate.

According to the information available, the second author from reference [98] within snippet [1] or reference [79] within snippet [5], a study by Coronel et al. is not specified. The study by Coronel et al. outlined the superiority of the epigenetic therapy (Hydralazine/Valproate plus Cisplatin/Topotecan) over standard combination chemotherapy (Cisplatin/Topotecan) in terms of progression-free survival (PFS) in advanced cervical cancer.

Since the second author is not specified in the search snippets, I am unable to provide a second author.
...
2025-04-11 15:55:08,601 - NCTProcessor - INFO - Extracting info from response (task: track_second_authors_multiple_pmids_any):
Based on the information gathered, here's the answer:

SA<Medina>

**Explanation:**

*   A study by Mani et al. evaluated the radiosensitizing effects of hydralazine in combination with valproic acid in SiHa cells and discovered that the triple combination of hydralazine, valproic acid, and cisplatin, correlated with the highest cytotoxic effects in radio-sensitized cervical cancer cells. L.A. Medina is listed as the second author of this paper.
...
2025-04-11 15:55:08,602 - NCTProcessor - INFO - Extracting info from response (task: track_second_authors_multiple_pmids_any):
Based on the search results, here's an analysis of studies comparing Interferon alfa-2b and Thalidomide, and the identification of potential second authors:

**Study Comparing Thalidomide + Interferon vs. Interferon Alone:**

*   A study mentioned in multiple search results ([2]) compared maintenance therapy with thalidomide plus interferon α-2b to interferon α-2b alone in elderly patients with multiple myeloma. This study found that the combination increased progression-free survival but not overall survival, with slightly more toxicity.

**Identifying the Second Author:**

To identify the second author, I need to look at the publication details of the study mentioned above. However, none of the search results provided a comprehensive list of authors for *that specific study*.

*However*, I can provide an example based on a similar study. Search result [5] details a "Randomized Phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma". The authors listed are: Tzeon-Jye Chiou, **Teng-Hsu Wang**, Tsu-Yi Chao, Sheng-Fung Lin, Jih-Luh Tang, Tsai-Yun Chen, Ming-Chih Chang, Erh-Jung Hsueh, Po-Min Chen.

In this example, the second author would be:

SA Teng-Hsu Wang
...
2025-04-11 15:55:08,602 - NCTProcessor - INFO - Extracting info from response (task: track_second_authors_multiple_pmids_any):
Based on the search results, particularly study [3], here's the requested information regarding a study comparing Interferon alfa-2b monotherapy to Interferon alfa-2b and Thalidomide in treating multiple myeloma:

*   **SA: Mileshkin** (Linda Mileshkin)

Please note that this information is based on the available search results and relates to a specific study. Other studies may exist with different authors and findings.
...
2025-04-11 15:55:08,603 - NCTProcessor - WARNING - Failed to extract any author.
2025-04-11 15:55:08,603 - NCTProcessor - INFO - Extracting info from response (task: track_second_authors_multiple_pmids_any):
Based on the information from the search results, here's an attempt to identify a second author from relevant papers:

One relevant paper is titled "Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer." According to the search snippet, the authors include: Cora Sternberg, Andrew Armstrong, Roberto Pili, Siobhan Ng, and many others.

Therefore, SA<Andrew Armstrong>
...
2025-04-11 15:55:08,603 - NCTProcessor - INFO - Accuracy: 0/5 (0.00%)
2025-04-11 15:55:08,604 - NCTProcessor - INFO - Saving results to results_second_authors_multiple_pmids_any.csv...
2025-04-11 15:55:08,606 - NCTProcessor - INFO - Results saved to results_second_authors_multiple_pmids_any.csv
2025-04-11 15:55:43,246 - NCTProcessor - INFO - Processing data/Hemonc_new_with_authors.csv with gemini-2.0-flash
2025-04-11 15:55:43,246 - NCTProcessor - INFO - Reading CSV file: data/Hemonc_new_with_authors.csv
2025-04-11 15:55:43,249 - NCTProcessor - INFO - Preparing input data...
2025-04-11 15:55:43,259 - NCTProcessor - INFO - Processing 5 examples using gemini-2.0-flash with tools using 8 threads...
2025-04-11 15:55:43,260 - google_genai.models - INFO - AFC is enabled with max remote calls: 10.
2025-04-11 15:55:43,260 - google_genai.models - INFO - AFC is enabled with max remote calls: 10.
2025-04-11 15:55:43,261 - google_genai.models - INFO - AFC is enabled with max remote calls: 10.
2025-04-11 15:55:43,262 - google_genai.models - INFO - AFC is enabled with max remote calls: 10.
2025-04-11 15:55:43,262 - google_genai.models - INFO - AFC is enabled with max remote calls: 10.
2025-04-11 15:55:45,661 - google_genai.models - INFO - AFC remote call 1 is done.
2025-04-11 15:55:45,908 - google_genai.models - INFO - AFC remote call 1 is done.
2025-04-11 15:55:46,010 - google_genai.models - INFO - AFC remote call 1 is done.
2025-04-11 15:55:46,267 - google_genai.models - INFO - AFC remote call 1 is done.
2025-04-11 15:55:48,218 - google_genai.models - INFO - AFC remote call 1 is done.
2025-04-11 15:55:48,219 - NCTProcessor - INFO - Processing results...
2025-04-11 15:55:48,220 - NCTProcessor - INFO - Extracting info from response (task: track_second_authors_multiple_pmids_any):
Based on the search results, the most relevant paper appears to be:

*   **Coronel et al. (2011)**, "A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer". This study, outlined in multiple search results ([1, 2, 3, 8, 9]), compares Cisplatin/Topotecan alone to Cisplatin/Topotecan with Hydralazine/Valproate.

While the second author isn't explicitly stated in the search snippets, knowing the first author and the paper title, I can search for that specifically.

Based on the additional search, the authors of the Coronel et al. (2011) paper are:

*   J. Coronel
*   L. Cetina
*   I. Pacheco
*   C. Trejo-Becerril
*   A. González-Fierro
*   E. de la Cruz-Hernandez
*   E. Perez-Cardenas
*   L...
2025-04-11 15:55:48,220 - NCTProcessor - INFO - Extracting info from response (task: track_second_authors_multiple_pmids_any):
Based on the information from the search results, specifically referencing the study by Coronel et al., here's the second author:

SA Cetina
...
2025-04-11 15:55:48,220 - NCTProcessor - INFO - Extracting info from response (task: track_second_authors_multiple_pmids_any):
Based on the search results, the study that best describes the efficacy of Interferon alfa-2b and Thalidomide compared to Interferon alfa-2b monotherapy when used to treat Multiple myeloma is:

*   **Randomized Phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma** by Chiou et al.

The second author of this paper is **SA Wang**.
...
2025-04-11 15:55:48,221 - NCTProcessor - INFO - Extracting info from response (task: track_second_authors_multiple_pmids_any):
Based on the search results, specifically referencing a study comparing thalidomide vs. thalidomide plus interferon alfa, the second author from the relevant paper is:

SA<Teng-Hsu Wang>

This is according to the study: Randomized Phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma. Cancer Invest. 2007 Apr-May;25(3):140-7. doi: 10.1080/07357900701208808. Authors: Tzeon-Jye Chiou, Teng-Hsu Wang, Tsu-Yi Chao, Sheng-Fung Lin, Jih-Luh Tang, Tsai-Yun Chen, Ming-Chih Chang, Erh-Jung Hsueh, Po-Min Chen.
...
2025-04-11 15:55:48,222 - NCTProcessor - INFO - Extracting info from response (task: track_second_authors_multiple_pmids_any):
Based on the information gathered, the paper that best describes the efficacy of Tasquinimod monotherapy compared to placebo for prostate cancer is:

*   **Reference:** Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2016 Aug 1;34(22):2636-43. doi: 10.1200/JCO.2016.66.9697. Epub 2016 Jun 13.

The second author of this paper is Andrew Armstrong.

SAAndrew Armstrong
...
2025-04-11 15:55:48,222 - NCTProcessor - INFO - Accuracy: 0/5 (0.00%)
2025-04-11 15:55:48,222 - NCTProcessor - INFO - Saving results to results_second_authors_multiple_pmids_any.csv...
2025-04-11 15:55:48,224 - NCTProcessor - INFO - Results saved to results_second_authors_multiple_pmids_any.csv
2025-04-11 15:56:20,250 - NCTProcessor - INFO - Processing data/Hemonc_new_with_authors.csv with gemini-2.0-flash
2025-04-11 15:56:20,250 - NCTProcessor - INFO - Reading CSV file: data/Hemonc_new_with_authors.csv
2025-04-11 15:56:20,252 - NCTProcessor - INFO - Preparing input data...
2025-04-11 15:56:20,265 - NCTProcessor - INFO - Processing 5 examples using gemini-2.0-flash with tools using 8 threads...
2025-04-11 15:56:20,266 - google_genai.models - INFO - AFC is enabled with max remote calls: 10.
2025-04-11 15:56:20,266 - google_genai.models - INFO - AFC is enabled with max remote calls: 10.
2025-04-11 15:56:20,267 - google_genai.models - INFO - AFC is enabled with max remote calls: 10.
2025-04-11 15:56:20,268 - google_genai.models - INFO - AFC is enabled with max remote calls: 10.
2025-04-11 15:56:20,268 - google_genai.models - INFO - AFC is enabled with max remote calls: 10.
2025-04-11 15:56:22,525 - google_genai.models - INFO - AFC remote call 1 is done.
2025-04-11 15:56:22,698 - google_genai.models - INFO - AFC remote call 1 is done.
2025-04-11 15:56:22,798 - google_genai.models - INFO - AFC remote call 1 is done.
2025-04-11 15:56:23,590 - google_genai.models - INFO - AFC remote call 1 is done.
2025-04-11 15:56:23,746 - google_genai.models - INFO - AFC remote call 1 is done.
2025-04-11 15:56:23,747 - NCTProcessor - INFO - Processing results...
2025-04-11 15:56:23,747 - NCTProcessor - INFO - Extracting info from response (task: track_second_authors_multiple_pmids_any):
Based on the search results, the most relevant study is a phase III clinical trial that evaluated the addition of hydralazine and valproate (HV) to cisplatin and topotecan (CT) in patients with advanced cervical cancer. Here's a breakdown:

*   **Study Design:** Randomized, placebo-controlled phase III trial.
*   **Treatment Groups:**
    *   Cisplatin + Topotecan + Hydralazine/Valproate (CT + HV)
    *   Cisplatin + Topotecan + Placebo (CT + PLA)
*   **Key Findings:** The study indicated a statistically significant advantage in progression-free survival (PFS) for the CT + HV group (10 months) compared to the CT + PLA group (6 months).

To find the second author of this study, I need to look at the publication details. Based on the search results, one relevant citation is:

*   Coronel et ...
2025-04-11 15:56:23,748 - NCTProcessor - INFO - Extracting info from response (task: track_second_authors_multiple_pmids_any):
Based on the information from the search results, here's the answer:

SA<Cetina>

**Explanation:**

*   Several sources ([1, 4, 5, 6, 7, 10]) refer to a study examining hydralazine and valproate in combination with cisplatin and topotecan for cervical cancer.
*   Specifically, source [10] identifies Coronel J, Cetina L, et al. as authors of a relevant study (NCT00064077). Therefore, Cetina is the second author.
...
2025-04-11 15:56:23,748 - NCTProcessor - INFO - Extracting info from response (task: track_second_authors_multiple_pmids_any):
Based on the search results, specifically referencing the study "Randomized Phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma" (Cancer Invest. 2007 Apr-May;25(3):140-7), the second author is:

SA: Teng-Hsu Wang
...
2025-04-11 15:56:23,748 - NCTProcessor - INFO - Extracting info from response (task: track_second_authors_multiple_pmids_any):
Based on the search results, a study comparing thalidomide vs. thalidomide plus interferon alfa (IFNα) exists.

According to "[1] Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: A", Chiou is a possible author of a relevant study.

Referring to "[3] Lenalidomide use in multiple myeloma (Review) - Spandidos Publications.", Ya-Nan Wang is the second author for this article.

Therefore, SAWang
...
2025-04-11 15:56:23,748 - NCTProcessor - INFO - Extracting info from response (task: track_second_authors_multiple_pmids_any):
Based on the search results, here's the information you requested, focusing on studies comparing Tasquinimod monotherapy to placebo in prostate cancer:

**Study 1:**

*   **Reference:** A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.
*   The median rPFS was 31.7 weeks in the tasquinimod arm and 22.7 weeks in the placebo arm.
*   The second author cannot be determined from the abstract.

**Study 2:**

*   **Reference:** Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer (Sternberg et al., 2016).
*   This phase III trial c...
2025-04-11 15:56:23,748 - NCTProcessor - INFO - Accuracy: 0/5 (0.00%)
2025-04-11 15:56:23,748 - NCTProcessor - INFO - Saving results to results_second_authors_multiple_pmids_any.csv...
2025-04-11 15:56:23,750 - NCTProcessor - INFO - Results saved to results_second_authors_multiple_pmids_any.csv
